📊 TSHA Key Takeaways
Is Taysha Gene Therapies, Inc. (TSHA) a Good Investment?
Taysha Gene Therapies maintains exceptional financial health with $276.6M in cash and 14x liquidity providing 6-7+ years of operational runway, significantly reducing near-term solvency risk. However, the company remains pre-revenue with consistent $40M+ annual operating losses, and investment merit depends entirely on clinical program success with no proven pathway to profitability visible in current fundamentals.
Taysha Gene Therapies, Inc. Key Strengths (TSHA)
- Exceptional cash position of $276.6M with minimal capex needs, providing substantial operational runway
- Strong balance sheet with 14.04x current ratio and conservative 0.23x debt-to-equity leverage
- Slight improvement in EPS loss trajectory (+5.6% YoY) indicating potential operational efficiency gains
TSHA Stock Risks: Taysha Gene Therapies, Inc. Investment Risks
- Zero revenue generation with no clear commercialization timeline or product approval visibility
- Annual operating burn of $40.9M requires successful R&D execution to justify cash deployment
- Clinical-stage biotech with high technical and regulatory risk; failed programs could rapidly deplete capital reserves
- Future financing likely required; equity dilution risk if clinical failures accelerate cash burn
Key Metrics to Watch
- Quarterly cash burn rate trend (acceleration vs. deceleration indicates program traction)
- Clinical trial progression and regulatory milestones for pipeline programs
- Months of cash runway remaining relative to program development timeline
- Any revenue generation from partnerships, licensing, or product approvals
Taysha Gene Therapies, Inc. (TSHA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 14.04x current ratio provides a solid financial cushion.
TSHA Profit Margin, ROE & Profitability Analysis
TSHA vs Healthcare Sector: How Taysha Gene Therapies, Inc. Compares
How Taysha Gene Therapies, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Taysha Gene Therapies, Inc. Stock Overvalued? TSHA Valuation Analysis 2026
Based on fundamental analysis, Taysha Gene Therapies, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Taysha Gene Therapies, Inc. Balance Sheet: TSHA Debt, Cash & Liquidity
TSHA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Taysha Gene Therapies, Inc.'s revenue has grown significantly by 291% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.36 indicates the company is currently unprofitable.
TSHA Revenue Growth, EPS Growth & YoY Performance
TSHA Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | N/A | -$21.5M | $-0.08 |
| Q3 2025 | N/A | -$25.5M | $-0.09 |
| Q2 2025 | $1.1M | -$20.9M | $-0.09 |
| Q1 2025 | $2.3M | -$21.5M | $-0.08 |
| Q3 2024 | $1.8M | -$25.5M | $-0.10 |
| Q2 2024 | $1.1M | -$20.9M | $-0.09 |
| Q1 2024 | $3.4M | -$17.6M | $-0.10 |
| Q3 2023 | $4.7M | -$26.5M | $-0.65 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Taysha Gene Therapies, Inc. Dividends, Buybacks & Capital Allocation
TSHA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Taysha Gene Therapies, Inc. (CIK: 0001806310)
📋 Recent SEC Filings
❓ Frequently Asked Questions about TSHA
What is the AI rating for TSHA?
Taysha Gene Therapies, Inc. (TSHA) has an AI grade of B with 65% confidence, based on fundamental analysis of SEC EDGAR filings.
What are TSHA's key strengths?
Claude: Exceptional cash position of $276.6M with minimal capex needs, providing substantial operational runway. Strong balance sheet with 14.04x current ratio and conservative 0.23x debt-to-equity leverage.
What are the risks of investing in TSHA?
Claude: Zero revenue generation with no clear commercialization timeline or product approval visibility. Annual operating burn of $40.9M requires successful R&D execution to justify cash deployment.
What is TSHA's revenue and growth?
Taysha Gene Therapies, Inc. reported revenue of $0.0.
Does TSHA pay dividends?
Taysha Gene Therapies, Inc. does not currently pay dividends.
Where can I find TSHA SEC filings?
Official SEC filings for Taysha Gene Therapies, Inc. (CIK: 0001806310) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is TSHA's EPS?
Taysha Gene Therapies, Inc. has a diluted EPS of $-0.12.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is TSHA's fundamental grade?
Based on our AI fundamental analysis in June 2026, Taysha Gene Therapies, Inc. has a B grade with 65% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is TSHA stock overvalued or undervalued?
Valuation metrics for TSHA: ROE of -20.0% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is TSHA's AI grade for 2026?
Our dual AI analysis gives Taysha Gene Therapies, Inc. a combined B grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is TSHA's free cash flow?
Taysha Gene Therapies, Inc.'s operating cash flow is $-40.9M, with capital expenditures of $24.0K.
How does TSHA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -20.0% (avg: 15%), current ratio 14.04 (avg: 2).